Potential value of high‐dose mizoribine as rescue therapy for ongoing acute humoral rejection

@article{Liu2005PotentialVO,
  title={Potential value of high‐dose mizoribine as rescue therapy for ongoing acute humoral rejection},
  author={Dage Liu and Takaaki Kobayashi and Takaharu Nagasaka and Itsuo Yokoyama and Yu Ma and Yuko Miwa and Takafumi Kuzuya and Kunio Morozumi and Tadashi Oikawa and Yasunobu Shimano and Oki Takeuchi and Kazuharu Uchida and Akimasa Nakao},
  journal={Transplant International},
  year={2005},
  volume={18}
}
Mizoribine (MZ) inhibits the proliferation of lymphocytes selectively via inhibition of inosine monophosphate dehydrogenase, like mycophenolate mofetil (MMF). The clinical dosage of MZ (2–5 mg/kg) is much lower than that of MMF (20–60 mg/kg). The purpose of this study was to examine whether high‐dose MZ would be effective for treatment of acute humoral rejection. Renal transplantation was performed in a different pig strain combination. Group 1 (n = 2) received no treatment. Group 2 (n = 4… 
Prophylactic treatment of antibody‐mediated rejection with high‐dose mizoribine and pharmacokinetic study *
TLDR
Higher doses of MZ efficiently prevented AMR and therapeutic drug monitoring is essential before clinical application, and effective Cmax seemed to be over 3 μg/ml at minimum.
Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers.
TLDR
Based on the favourable safety profile and current pharmacokinetic information, a new starting dose in the 6-12 mg kg(-1) day (-1) range is recommended in the up to 3 months acute phase following transplantation, with dose reduction recommended only if the function of the transplanted kidney is impaired.
Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients
TLDR
CREB1 and SLC28A3 genotypes, as well as SCr, are identified as determinants in predicting inter-individual MZR PK differences in renal transplant recipients.
Combination Effect of Mycophenolate Mofetil with Mizoribine on Cell Proliferation Assays and in a Mouse Heart Transplantation Model
TLDR
The combination of MMF and MZ showed mild synergism effects in the inhibition of MLR and strong synergistic effects in a mouse heart transplantation model.
Mizoribine as Sole Immunosuppressive Agent in Islet Xenotransplantation Models: A Candidate Immunosuppressant Causing no Adverse Effects on Islets
TLDR
MZ showed immunosuppressive effects in an experimental islet xenotransplantation model without adverse effects on endocrine function of islet grafts and showed significant suppression of lymphocyte infiltration by MZ administration.
Prediction of mizoribine pharmacokinetic parameters by serum creatinine in renal transplant recipients
TLDR
Renal function plays as an essential factor that contributes to great inter-individual MZR PK variation and both C0 and Cmax are suitable for evaluating MZr exposure in the body.
Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics
TLDR
Therapeutic drug monitoring of both mizoribine and MTX is expected to improve their clinical efficacy in the treatment of rheumatoid arthritis.
Advantages and Disadvantages of Conditional Estimation Methods for Population Pharmacokinetic Analysis of Mizoribine
Mizoribine, an orally available immunosuppressive agent, has been approved in Japan since 1984 to prevent the rejection of kidney transplants. Mizoribine has subsequently been approved for the
...
...

References

SHOWING 1-10 OF 35 REFERENCES
RS-61443--a new, potent immunosuppressive agent.
TLDR
Long-term administration of RS-61443 (20 mg/kg/day) did not cause nephrotoxicity, hematot toxicity, or hepatotoxicity, with the exception of a slight elevation of the alkaline phosphatase levels.
EFFECTS OF COMBINATION CYCLOSPORINE/MIZORIBINE IMMUNOSUPPRESSION ON CANINE RENAL ALLOGRAFT RECIPIENTS1,2,3
TLDR
Combination cyclosporine/mizoribine immunosuppression enhanced canine renal allograft survival in this study and availability of an intravenous form of mizorIBine would facilitate immunoregulation during periods of variable intestinal absorption or renal excretion.
PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION
TLDR
MMF significantly reduced the rate of biopsy-proven rejection or other treatment failure during the first 6 months after transplantation and was well tolerated, although the 3 g dose was somewhat less well tolerated.
Mizoribine and mycophenolate mofetil.
  • H. Ishikawa
  • Biology, Medicine
    Current medicinal chemistry
  • 1999
Both mizoribine (MZR) and mycophenolate mofetil (MMF) are immunosuppressive agents that inhibit the proliferation of lymphocytes selectively, via inhibition of IMPDH. MZR is a nucleoside of the
USE OF MYCOPHENOLATE MOFETIL AS RESCUE THERAPY AFTER PEDIATRIC LIVER TRANSPLANTATION
TLDR
Preliminary results suggest that MMF is an effective and safe immunosuppressant in pediatric LT recipients, and its use is hampered by frequent gastrointestinal and hematological side-effects.
RS-61443 reverses acute allograft rejection in dogs.
TLDR
High-dose therapy with RS-61443 can successfully reverse acute kidney allograft rejection in dogs in a high proportion of cases, resulting in a return of serum creatinine to prerejection levels.
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
TLDR
This study demonstrated that MMF administered at a dosage of 2 g or 3 g daily, in combination with maintenance CsA and corticosteroids as triple therapy following ATGAM® induction therapy, is more effective than an otherwise identical regimen that includes azathioprine instead of MMF in preventing acute allograft rejection in first cadaveric renal transplant patients.
MIZORIBINE PHARMACOKINETICS AND PHARMACODYNAMICS IN A CANINE RENAL ALLOGRAFT MODEL OF LOCAL IMMUNOSUPPRESSION1,2
TLDR
It is concluded that at local doses required to achieve immunosuppression, the transplanted kidney was not able to extract enough MZB to prevent death from systemic toxicity, presumably as a result of saturation of renal elimination mechanisms, so that an overall survival benefit was not realized.
Effects of mizoribine on canine renal allograft recipients.
TLDR
Serum mizoribine concentrations were greater in dogs undergoing rapid allograft rejection because of compromised renal excretion of the drug, which resulted in a rapid onset of gastroenteritis.
Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation.
TLDR
It is suggested that a therapeutic approach combining PE and tacrolimus-mycophenolate mofetil rescue has the potential to improve the outcome of AHR.
...
...